For psychedelic medicines to reach as many patients as possible, developers need to secure buy-in at every level of the
Awakn Life Sciences recently signed a memorandum of understanding with Devon Partnership NHS Trust and the University of Exeter, to
To strengthen the adoption of psychedelic-assisted therapies, drug developers are striving to minimise their cost – with shorter lasting tryptamines.
Member of Parliament Crispin Blunt has championed the campaign to reschedule psilocybin for scientific and research purposes in the UK.
Cybin became the first psychedelic healthcare company to list on the New York Stock Exchange, with its psilocybin formulation to
At Prime Minister’s Questions on 19 October, Boris Johnson responded to Tory MP Crispin Blunt’s call to reschedule psilocybin. Johnson
Numinus has completed C$40.3 million in bought deal financing and recently reported quarterly revenues over C$500,000. In September the company